RESEARCH

The landscape of antibiotic usage among COVID-19 patients in the early phase of pandemic: a Malaysian national perspective

Izzati-Nadhirah Mohamad¹, Calvin Ke-Wen Wong¹, Chii-Chii Chew², E-Li Leong²*, Biing-Horng Lee¹, Cheng-Keat Moh¹, Komalah Chenasammy¹, Steven Chee-Loon Lim³ and Hong-Bee Ker³

Abstract

Background: During the early phase of the COVID-19 pandemic, antibiotic usage among COVID-19 patients was noted to be high in many countries. The objective of this study was to determine the prevalence of antibiotic usage and factors affecting antibiotic usage among COVID-19 patients during the early phase of the COVID-19 pandemic in Malaysia.

Methods: This was a cross-sectional study that involved reviewing medical records of COVID-19 Malaysian patients aged 12 and above who were diagnosed with COVID-19 and received treatment in 18 COVID-19 hospitals from February to April 2020. A minimum sample of 375 patients was required. A binary logistic regression analysis was performed to determine factors associated with antibiotic usage. Variables with \( p < 0.05 \) were considered statistically significant.

Results: A total of 4043 cases were included for analysis. The majority of the patients (87.6%) were non-smokers, male (65.0%), and had at least one comorbidity (37.0%). The median age was 35 years (IQR: 38). The prevalence of antibiotic usage was 17.1%, with 5.5% of them being prescribed with two or more types of antibiotics. The most frequent antibiotics prescribed were amoxicillin/clavulanic acid (37.8%), ceftriaxone (12.3%), piperacillin/tazobactam (13.3%), azithromycin (8.3%), and meropenem (7.0%). Male patients (adjusted OR 1.53), who had a comorbidity (adjusted OR 1.36), associated with more severe stage of COVID-19 (adjusted OR 6.50–37.06), out-of-normal range inflammatory blood parameters for neutrophils, lymphocytes, and C-reactive protein (adjusted OR 2.04–3.93), corticosteroid use (adjusted OR 3.05), and ICU/HDU admission (adjusted OR 2.73) had higher odds of antibiotic use.

Conclusions: The prevalence of antibiotic usage in the early phase of the COVID-19 pandemic was low, with amoxicillin/clavulanic acid as the most common antibiotic of choice. The study showed that clinicians rationalized antibiotic usage based on clinical assessment, supported by relevant laboratory parameters.

Keywords: Anti-bacterial agents, COVID-19, Prevalence, Infectious disease, Malaysia, Antibiotic use

Background

In the early phase of the COVID-19 pandemic, the virus infected more than 3 million people, causing about 200,000 deaths globally as of April 30, 2020 [1]. In this period, the prevalence of SAR-CoV-2 co-infection is low (14 to 25%), with bacterial co-infection ranging from 5 to 11% [2]. Despite a relatively low bacterial co-infection rate, the prevalence of antibiotic usage in patients with...
COVID-19 infection was nevertheless considerably high. A research rapidly reviews studies researching on antibiotic usage in the early phase of pandemic revealed that 82.3% of 10, 329 COVID-19 patients (82.3%) received antibiotics therapy without regard to the severity of COVID-19 infection [3]. A meta-analysis shows that approximately 75% of patients with COVID-19 admitted to hospitals were given an antibiotic; yet, only 8% of the patients were confirmed with bacterial co-infection [4]. A similar pattern is seen among critically ill patients in which the rate of superinfection in COVID-19 patients was 13.5%, but 75.4 to 94% of them were treated with antibiotics [3, 5].

In the early outbreak of COVID-19, the nature of the disease was not clearly understood and lacked guidelines in managing COVID-19 patients with bacterial co-infection. Most of the physicians (83%) from 23 countries reported adapting local community-acquired pneumonia for antibiotic use in patients with COVID-19 with bacterial co-infection [6]. The antibiotic usage was shown to be biphasic in a study from the West, with amoxicillin/clavulanate being the most commonly prescribed antibiotic during the first wave of the pandemic for empirical coverage of all COVID-19 pneumonia cases, while other broad-spectrum antibiotics being the most commonly prescribed antibiotic during the second wave in April 2020, with a slight decrease in amoxicillin/clavulanate usage when more patients were admitted to intensive care units (ICU) [7]. This coincides with a study that showed that there was a peak of new ICU admissions in April 2020 [8]. When patients progress into severe disease and require critical care, broad-spectrum antibiotics are used empirically or prophylactically to prevent secondary bacterial infection [9]. The top usage of antibiotics in COVID-19 patients suspected of bacterial co-infection is azithromycin, ceftriaxone, cefepime, moxifloxacin, meropenem, and piperacillin/tazobactam [3, 10]. Consistently, physicians reported that β-lactams plus β-lactamase inhibitors or macrolides or fluoroquinolones alone (52.4%) were most frequently prescribed to COVID-19 patients at the beginning of the pandemic outbreak. In patients who were critically ill, piperacillin/tazobactam was the most commonly prescribed antibiotic [11].

Independent factors that affect the decision of a physician in prescribing an antibiotic include advanced age, presence of comorbidity, February–March 2020 admissions, symptoms of dry cough, fever, dyspnoea, flu-like, and elevated C-reactive protein (CRP) biomarkers [4, 12], procalcitonin [11], long hospital length of stay with a median of 12 days, admission to the ICU, and the necessity for mechanical ventilation [13]. Given variations in the management of COVID-19 in different countries, where some countries admit all COVID-19 patients while others only admit patients with severe symptoms, the factors affecting the use of antibiotic agents could be varied and influenced by the health policy that is unique to each country.

The distribution of antibiotic usage according to different region in the world, despite varying, it is considerably substantial. East and Southeast Asia (excluding China) reporting the highest (87.5%) and Europe the lowest (63.1%) [4]. Malaysia being one of the Southeast Asian countries, we are uncertain if the usage of antibiotics is as high as those reported in other countries in the same region. Additionally, reporting this data on a national scale would allow researchers and clinicians to gain insight into the extent of antibiotic usage in comparison to other countries, usage before the pandemic and the latter phase of the pandemic. This would also assist clinicians to estimate if multidrug-resistant bacteria is likely to occur in the future if there is any overuse of antibiotic agents [14]. This study aimed to determine the prevalence of antibiotic usage, the types of antibiotic agents, and the associated risk factors of COVID-19 patients who received antibiotics from a national perspective during the early phase of the COVID-19 pandemic.

Methods
Study design
This retrospective study involved reviewing medical records of COVID-19 positive patients. All Malaysian patients aged 12 years and above, who were RT-PCR confirmed COVID-19 and received treatment in 18 government-funded COVID-19 hospitals from 1st of February to 30th of April in 2020 were sampled. Medical officers who treated these patients were in-charge in entering the patients’ medical records real time into a national database (REDCap© system) developed and managed by the Infectious Diseases Unit and Clinical Research Centre of Hospital Sungai Buloh.

Approval was granted for researchers to access data relevant to antibiotic use. The administrator of the database helped to extract anonymous patients’ details including social demography (age, gender, smoking status, comorbidity), symptoms when presenting to the healthcare facilities, duration of hospitalization, types of ward admitted (normal ward, ICU or high dependency unit [HDU]), clinical severity stage [15], antibiotic regime, corticosteroid usage, full blood count (FBC) and renal function tests on admission, CRP, requirement of oxygen, and patient outcome (alive at the point of discharge or transfer to secondary healthcare facilities for continued observation or death). While there was lack of clear guidance for handling microbiological specimens early in the pandemic, cultures and sensitivity test was not
conducted on COVID-19 patient suspected with bacterial co-infection [16]. Hence, the microbiology data were not available. Of note, stages 1 to 3 for clinical severity for COVID-19 classification use in Malaysia [15] correspond to non-severe, while stages 4 and 5, respectively, correspond to severe and critical categories defined by the World Health Organization for COVID-19 severity [14] (Table 1).

Sample size and sampling method
The prevalence of antibiotic usage among patients diagnosed with COVID-19 during early phase of pandemic reported by other countries ranged from 58 to 71% [11]. By using sample size calculation for prevalence study [17], a minimum sample size of 375 was required to achieve precision of 5% and confidence level of 95% when 58% of the patients with COVID-19 were assumed to be prescribed with an antibiotic upon admission to the hospital. To gain an overview of antibiotic usage in the national perspectives, all medical records of the COVID-19 patients that fulfilled the inclusion were sampled.

Data analysis
IBM SPSS® Statistics Version 20.0 was used to perform descriptive analysis on the data. The prevalence of antibiotic usage was calculated as the proportion of patients prescribed at least one antibiotic. Antibiotics were further classified according to the antibiotic drug class. A binary logistic regression analysis was performed to determine factors associated with the prescribing of antibiotics during hospitalization. Univariate analysis was employed to determine the variables with a $p$-value < 0.05 that were needed for multivariate analysis. The variables included for multivariate analysis include age, gender, number of comorbidities, smoking status, clinical severity on admission, the most severe clinical classification during hospitalization, white blood cell count, platelets, neutrophils, lymphocytes, CRP, duration of hospitalization, use of anti-viral agents, use of anti-malarial agents, corticosteroid therapy and ICU/HDU admission. Stepwise backward logistic regression analysis was used to determine the final model that predicts the use of antibiotics when a COVID-19 patient is hospitalized. There was no detectable multicollinearity between the variables. Model fitness was tested using the Hosmer–Lemeshow goodness-of-fit test.

Results
The medical records of 4043 COVID-19 patients were included for analysis after eliminating 840 cases consisting of foreigners and children under the age of 12. Their age ranged between 12 and 95 years, with the median age of 38 (IQR: 38.0). Most of them were male (65.0%), Malay (77.2%), had hypertension (20.4%), and were non-smokers (87.6%). One-fifth (20.6%) had one comorbidity, while approximately 16% had at least two comorbidities, and a patient with seven comorbidities was noted (Table 2).

Most of them presented with symptoms of fever (38.7%) and cough (40.1%). They were classified stage 1 (40.4%) and stage 2 (36.8%) upon admission to the hospitals. The majority of them remained in stage 1 (33.3%) and stage 2 (33.3%). The proportion of patients at stage 3 increased from 15.9 to 22.2% during the hospital stay. Notably, the number of patients at stage 5 was increased from 57 (1.4%) on admission to 169 (4.2%) during hospitalization. Most of the biomarkers were normal for FBC and renal function tests except haematocrit (68.3%) and serum creatinine (58.0%). About one-tenth of them had abnormal profile in platelet (11.4%) and neutrophil counts (11.6%). The median duration of hospitalization was 11 days (IQR: 9.00). Five percent ($n = 193$) required intensive care, while 2% ($n = 77$) died (Table 3).

The number of patients prescribed antibiotic treatment increased from 524 (13.0%) on admission to 690 (17.1%)

### Table 1  The stages of COVID-19 severity in Malaysia corresponding to the classification of World Health Organization

| Clinical stage of COVID-19 severity in Malaysia [15] | COVID-19 severity based on World Health Organization [14] |
|------------------------------------------------------|----------------------------------------------------------|
| Stage 1: Asymptomatic                                 | Non-severe, Absence of sign of severe or critical disease |
| Stage 2: Symptomatic, no pneumonia                   | Severe                                                  |
| Stage 3: Symptomatic, pneumonia                      | Critical                                                |
| Stage 4: Symptomatic, pneumonia, requiring supplemental oxygen | Severe conditions                                       |
| Stage 5: Critically ill with multi-organ involvement  | Critical, Acute respiratory distress syndrome, Sepsis, Septic shock, Require life-sustaining therapies |

$SpO_2$ oxygen saturation via pulse oximeter
patients during hospitalization. Of those who were prescribed antibiotics, most of them were given one antibiotic (67.7–82.1%) and about 13 to 16% of them received two antibiotic therapies. Notably, two patients were given nine antibiotics throughout hospital stay. Patients who were administered at least three types of antibiotics increased from 25 (4.8%) to 107 (15.5%) during the period of admission to hospitalization.

The increased usage of antibiotics from admission to hospitalization was seen in β-lactam plus β-lactamase inhibitor, third and fourth generation cephalosporin, macrolides, penicillin, carbapenems, vancomycin, polymyxins, fluoroquinolones, and co-trimoxazole. The most commonly prescribed antibiotics upon patient admission were amoxicillin plus clavulanic acid, ceftriaxone and azithromycin. Meanwhile, addition of piperacillin/

| Table 2 | Demographic characteristic of COVID-19 patients, (n = 4043) |
|----------------|-----------------|----------------|----------------|
| Variables       | n (%) Antibiotic use | p-value*       |
| Age             | ≤ 65 years       | 3720 (92.0) | 572 (15.4) | < 0.001 |
|                 | > 65 years, median (IQR) | 323 (8.0) | 126 (38.9) |
| Gender          | Male             | 2628 (65.0) | 488 (18.6) | < 0.001 |
|                 | Female           | 1415 (35.0) | 21 (14.8)  |
| Ethnicity       | Malay            | 3119 (77.2) | 498 (16.0) | < 0.001a |
|                 | Chinese          | 333 (8.2)  | 67 (20.1)  |
|                 | Indian           | 115 (2.8)  | 18 (15.7)  |
|                 | Orang Asli Semenanjung | 4 (0.1) | 0 (0.0)   |
|                 | Bumiputera Sabah | 191 (4.7)  | 64 (33.5)  |
|                 | Bumiputera Sarawak | 281 (7.0) | 51 (18.1)  |
| Number of comorbidities | No comorbidity | 2549 | 258 (10.1) | < 0.001b |
|                 | 1                | 834 (20.6) | 205 (24.6) |
|                 | 2                | 373 (9.2)  | 120 (32.2) |
|                 | 3                | 194 (4.8)  | 74 (38.1)  |
|                 | 4                | 68 (1.7)   | 31 (45.6)  |
|                 | 5                | 20 (0.5)   | 7 (35.0)   |
|                 | 6                | 4 (0.1)    | 2 (50.0)   |
|                 | 7                | 1 (0.02)   | 1 (100.0)  |
| Types of comorbidities | Hypertension | 824 (20.4) | 270 (32.8) | < 0.001 |
|                 | Diabetes mellitus | 517 (12.8) | 204 (39.5) | < 0.001 |
|                 | Dyslipidaemia    | 215 (5.3)  | 49 (22.8)  | 0.028 |
|                 | Asthma           | 176 (4.4)  | 35 (19.9)  | 0.347 |
|                 | Chronic cardiac disease | 172 (4.3) | 64 (37.2) | < 0.001 |
|                 | Chronic kidney disease | 92 (2.3) | 60 (65.2) | < 0.001 |
|                 | Obesity          | 73 (1.8)   | 19 (26.0)  | 0.046 |
|                 | Malignant neoplasm | 40 (1.0)  | 15 (37.5)  | 0.001 |
|                 | Rheumatologic disorder | 33 (0.8) | 13 (39.4) | 0.001 |
|                 | Chronic neurological disorder | 32 (0.8) | 12 (37.5) | 0.002 |
|                 | Chronic pulmonary disease | 28 (0.7) | 19 (67.9) | < 0.001 |
|                 | Liver disease    | 10 (0.3)   | 2 (20.0)   | 0.822 |
|                 | Chronic hematologic disease | 7 (0.2) | 0 (0.0) | 0.103a |
|                 | AIDS/HIV         | 7 (0.2)    | 0 (0.0)    | 0.103 |
|                 | Dementia         | 4 (0.1)    | 1 (25.0)   | 0.697# |
| Smoking         | Smoker           | 500 (12.4) | 53 (16.9)  | 0.851 |
|                 | Non-smoker       | 3543 (87.6) | 645 (17.3) |

IQR interquartile range; AIDS acquired immunodeficiency syndrome; HIV human immunodeficiency virus

* Chi-square analysis of Malay and non-Malay ethnicity

# Chi-square analysis of no comorbidity vs 1, 2 and more than 2 comorbidities

* Chi-Square test

# Fisher's Exact test
Table 3 Clinical characteristic of COVID-19 patients, \((n = 4043)\)

| Variables                                      | \(n (%)\) | Antibiotic use* | \(p\)-value* |
|------------------------------------------------|------------|-----------------|--------------|
| Symptoms of presentation                       |            |                 |              |
| Cough                                          | 1620 (40.1) | 457 (28.2)      | \(<0.001\)   |
| Fever                                          | 1565 (38.7) | 433 (27.7)      | \(<0.001\)   |
| Sore throat                                     | 713 (17.6)  | 149 (20.9)      | 0.005        |
| Rhinorrhoea                                     | 550 (13.6)  | 104 (18.9)      | 0.272        |
| Dyspnoea                                        | 284 (7.0)   | 142 (50.0)      | \(<0.001\)   |
| Diarrhoea                                       | 279 (6.9)   | 100 (35.8)      | \(<0.001\)   |
| Myalgia                                        | 217 (5.4)   | 52 (24.0)       | 0.007        |
| Malaise                                         | 183 (4.5)   | 72 (38.7)       | \(<0.001\)   |
| Anosmia                                         | 155 (3.8)   | 10 (6.5)        | \(<0.001\)   |
| Headache                                        | 154 (3.8)   | 26 (16.9)       | 0.898        |
| Arthralgia                                      | 114 (2.8)   | 29 (25.4)       | 0.019        |
| Nausea/vomiting                                 | 100 (2.5)   | 38 (38.0)       | \(<0.001\)   |
| Ageusia                                         | 38 (0.9)    | 3 (7.9)         | 0.125f       |
| Abdominal pain                                  | 36 (0.9)    | 13 (36.1)       | 0.003        |
| Chest pain                                      | 50 (1.2)    | 21 (42.0)       | \(<0.001\)   |
| Skin rash                                       | 9 (0.2)     | 2 (22.2)        | 0.659f       |
| Conjunctivitis                                  | 9 (0.2)     | 0 (0.0)         | 0.374f       |
| Wheezing                                        | 6 (0.1)     | 3 (50.0)        | 0.104f       |
| Ear pain                                        | 5 (0.1)     | 0 (0.0)         | 0.168f       |
| Haemorrhage                                     | 3 (0.1)     | 3 (100.0)       | \(<0.005g\)  |
| Clinical severity stage on admission\(g\)       |            |                 |              |
| Stage 1                                         | 1634 (40.4)| 64 (3.9)        | \(<0.001\)   |
| Stage 2                                         | 1487 (36.8)| 244 (16.4)      |              |
| Stage 3                                         | 644 (15.9)  | 186 (28.9)      |              |
| Stage 4                                         | 221 (5.5)   | 145 (69.0)      |              |
| Stage 5                                         | 57 (1.4)    | 51 (17.1)       |              |
| Worst clinical stage\(g\)                      |            |                 |              |
| Stage 1                                         | 1345 (33.3)| 16 (1.2)        | \(<0.001\)   |
| Stage 2                                         | 1347 (33.3)| 154 (11.4)      |              |
| Stage 3                                         | 896 (22.2)  | 200 (22.3)      |              |
| Stage 4                                         | 287 (7.1)   | 166 (60.1)      |              |
| Stage 5                                         | 168 (4.2)   | 157 (93.5)      |              |
| Out of normal range FBC (on admission)          |            |                 |              |
| White blood cells \((n = 3661)\)               | 302 (8.3)   | 111 (15.9)      | \(<0.001\)   |
| Haemoglobin \((n = 3661)\)                     | 146 (4.0)   | 65 (9.3)        | \(<0.001\)   |
| Hematocrit \((n = 3638)\)                      | 2486 (68.3) | 271 (39.3)      | \(<0.001\)   |
| Platelets \((n = 3661)\)                       | 417 (11.4)  | 102 (14.6)      | \(<0.001\)   |
| Neutrophil count \((n = 3548)\)                | 413 (11.6)  | 152 (21.8)      | \(<0.001\)   |
| Lymphocyte count \((n = 3573)\)                | 141 (4.0)   | 55 (7.9)        | \(<0.001\)   |
| Out of normal range renal function test (on admission) | | | |
| Serum creatinine \((n = 3493)\)                | 2025 (58.0) | 367 (52.6)      | 0.005        |
| Blood urea nitrogen \((n = 3505)\)             | 678 (19.3)  | 228 (32.7)      | \(<0.001\)   |
| Sodium \((n = 3507)\)                          | 469 (13.4)  | 230 (33.0)      | \(<0.001\)   |
| Potassium \((n = 3500)\)                       | 855 (24.4)  | 186 (26.6)      | \(<0.001\)   |
| Out of normal range CRP \((n = 2522)\)         | 346 (13.7)  | 188 (26.9)      | \(<0.001\)   |
| Use of anti-fungal agents \(\text{\textsuperscript{a}}\) | 50 (1.2) | 40 (80.0) | \(<0.001\) |
| Use of anti-malarial agents \(\text{\textsuperscript{a}}\) | 1935 (47.9) | 570 (29.5) | \(<0.001\) |
| Use of anti-viral agents \(\text{\textsuperscript{a}}\) | 1020 (33.6) | 549 (53.8) | \(<0.001\) |
| Oxygen therapy \(\text{\textsuperscript{a}}\) | 459 (11.4) | 329 (71.7) | \(<0.001\) |
| Corticosteroid therapy \(\text{\textsuperscript{a}}\) | 124 (3.1) | 108 (87.1) | \(<0.001\) |
| Admission to ICU/HDU \(\text{\textsuperscript{a}}\) | 192 (4.8) | 176 (91.7) | \(<0.001\) |
| Duration of hospitalization, median (IQR) \(\text{\textsuperscript{a}}\) | 11.00 (9.00) | | \(<0.001\) |
tazobactam, and meropenem were the most frequently given antibiotics during hospitalization (Table 4).

A higher odds of antibiotics usage was observed among patients who were male (adjusted OR [AOR] 1.53), had a comorbidity (AOR 1.36), with severity of disease classification of stage 2 to 5 (AOR 4.32 to 30.85), tested out-of-normal range biomarkers for neutrophil (AOR 2.31), lymphocyte counts (AOR 2.04), and CRP (AOR 3.34), hospitalized more than 7 days (AOR 1.89 to 3.81), had corticosteroids therapy (AOR 3.05), prescribed with antiviral agents (AOR 6.38) and anti-malarial agents (AOR 1.63), and had admitted to HDU or ICU (AOR 2.73) (Table 5).

Discussion
This study assessed the use of antibiotics in the early wave of the COVID-19 outbreak between February and April 2020 in Malaysia. At the beginning of the pandemic, all patients confirmed positive for COVID-19 infection were required to be admitted to government-funded facilities [18]. Therefore, we were able to include all the medical records of Malaysian patients with COVID-19 in the early phase of the pandemic. It allowed us to conduct a thorough analysis of the prevalence of antibiotic use and the choice of antibiotic agent prescribed to the COVID-19 patients suspected of bacterial co-infection. The factors associated with antibiotic use were critical information that allowed clinicians to make decisions when prescribing antibiotics for the COVID-19 suspected bacterial co-infection, especially when microbiological testing was not permitted in certain conditions. The study findings provide a full picture of antibiotic use during the early phase of pandemic and permit researchers to conduct further research on the changes in the antibiotic usage pattern at different phases of COVID-19.

Our study showed that the national antibiotic usage in this country was below 20% in the early outbreak of COVID-19. In the early phase of the pandemic, 67% of COVID-19 patients were treated with empirical antibiotics in the United States, [10]. A higher percentage of antibiotic usage was seen in China and Indonesia (70.5 to 95.0%) [19–22]. The high prevalence of antibiotics usage in the pandemic was further confirmed by two meta-analyses [23, 24], in which 71.9 to 74.0% of COVID-19 patients were given antibiotics, where only 1.0 to 19.7% were confirmed with bacterial co-infection [10, 20, 21, 23–27]. The prevalence of national antibiotic usage among COVID-19 patients in Malaysia was relatively lower compared to that of other countries. This can be attributed to the initial understanding among the Infectious Disease Team in Malaysia during the early phase of pandemic that COVID-19 is a viral infection and is in line with the recommendation of the World Health Organization where antibiotics should not be considered unless suspicious of bacterial co-infection in COVID-19 patients [16, 28]. Hence, the antibiotic treatment regime was not included in the Malaysian guidelines for clinical management of COVID-19 confirmed cases [16]. The antibiotic treatment guide was added to the guideline during the later stages of the pandemic, stating that where there is evidence of bacterial co-infections, antibiotics should be given without waiting for microbiological results [29].

The types of antibiotics used in this study were similar to those used in a study looking into antibiotic usage in a few Western countries [11], which preferred β-lactam/β-lactamase inhibitors, cephalosporins, and macrolides. If a patient was in ICU or required oxygen therapy, piperacillin/tazobactam and meropenem were the choices. Despite the fact that information on antibiotic regimes was not included in the interim Malaysian guidelines for clinical management of COVID-19 [16], the choices of antibiotic usage for COVID-19 patients with suspected bacterial co-infection were as recommended in the Malaysian National Antibiotic Guideline 2019 for pneumonia [30].
Although ceftriaxone was the second most common antibiotic used among COVID-19 patients in other countries such as the United States and Bangladesh, where it was prescribed at a rate of nearly 54.0% [10, 32], the usage was low in this study (12.3%). In a meta-analysis, fluoroquinolone and 3rd generation cephalosporins accounted for 56.8 to 76.0% of the total antibiotic prescriptions [4, 21, 23, 33], which was substantially higher than the local usage of 0.2% to 12.3%. With regard to the carbapenem group of antibiotics, developing countries like Bangladesh prescribed 40.9% as compared to this country, which recorded a single-digit percentage of about 7% carbapenem utility during hospitalization [32]. The difference may be attributed to the different healthcare systems, the provision of antibiotics and infection control measures taken during the pandemic.

### Table 4 Antibiotics and related treatments for COVID-19 patients during admission and hospitalization

| Variable                                | Admission, n (%)  | Hospitalization, n (%) |
|-----------------------------------------|-------------------|------------------------|
|                                         | n = 524<sup>a</sup> | n = 690<sup>a</sup>    |
| Number of antibiotic prescribed per patient  |                   |                        |
| 1                                       | 430 (82.1)        | 467 (67.7)             |
| 2                                       | 69 (13.2)         | 116 (16.8)             |
| 3                                       | 16 (3.1)          | 52 (7.5)               |
| 4                                       | 5 (1.0)           | 24 (3.5)               |
| 5                                       | 2 (0.4)           | 15 (2.3)               |
| 6                                       | 0 (0.0)           | 11 (1.6)               |
| 7                                       | 1 (0.2)           | 1 (0.1)                |
| 8                                       | 1 (0.2)           | 2 (0.3)                |
| 9                                       | 0 (0.0)           | 2 (0.3)                |
| Fluoroquinolones                        |                   |                        |
| Ciprofloxacin                           | 1 (0.2)           | 4 (0.4)                |
| Moxifloxacin                            | 1 (0.2)           | 1 (0.1)                |
| Cephalosporins                          |                   |                        |
| Fourth generation: cefepime             | 12 (1.8)          | 49 (4.3)               |
| Third generation: ceftriaxone           | 81 (12.3)         | 139 (12.3)             |
| Third generation: cefoperazone          | 1 (0.2)           | 0 (0.0)                |
| Third generation: ceftazidime           | 6 (0.9)           | 16 (1.4)               |
| Second generation: cefuroxime           | 5 (0.8)           | 11 (1.0)               |
| First generation: cephalixin            | 1 (0.2)           | 2 (0.2)                |
| First generation: cefazolin             | 1 (0.2)           | 2 (0.2)                |
| Macrolides                              |                   |                        |
| Erythromycin                            | 3 (0.5)           | 3 (0.3)                |
| Azithromycin                            | 64 (9.7)          | 94 (8.3)               |
| Glycopeptides                           |                   |                        |
| Vancomycin                              | 4 (0.6)           | 20 (1.8)               |
| Polymyxins                              |                   |                        |
| Colistin                                | 2 (0.3)           | 19 (1.7)               |
| Polymyxin B                             | 1 (0.2)           | 10 (0.9)               |
| β-lactam/β-lactamase inhibitor          |                   |                        |
| Amoxicillin/clavulanic acid             | 375 (56.7)        | 428 (37.8)             |
| Piperacillin/tazobactam                 | 53 (8.0)          | 151 (13.3)             |
| Ampicillin/sulbactam                    | 16 (2.4)          | 43 (3.8)               |
| Penicillin                              |                   |                        |
| Amoxicillin                             | 3 (0.5)           | 6 (0.5)                |
| Cloxacillin                             | 7 (1.1)           | 19 (1.7)               |
| Tetracycline                            |                   |                        |
| Doxycycline                             | 2 (0.3)           | 9 (0.8)                |
| Lincosamides                            |                   |                        |
| Clindamycin                             | 2 (0.3)           | 4 (0.4)                |
| Co-trimoxazole                          | 4 (0.6)           | 16 (1.4)               |
| Carbapenem                              |                   |                        |
| Imipenem                                | 0 (0.0)           | 4 (0.4)                |
| Meropenem                               | 12 (1.8)          | 79 (7.0)               |
| Nitroimidazoles                         |                   |                        |
| Metronidazole                           | 4 (0.6)           | 4 (0.4)                |
| Corticosteroid usage (n = 4043)         |                   |                        |
| -                                       | –                 | 124 (3.1)              |
| Oxygen therapy (n = 4043)               |                   |                        |
| Non-invasive                            | 221 (5.4)         | 324 (8.0)              |
| Invasive                                | 50 (1.2)          | 135 (3.3)              |

<sup>a</sup>Total number of patients prescribed antibiotic(s)
### Table 5  Factors associated with antibiotics usage among COVID-19 during hospitalization

| Variables                          | Simple logistic regression | Multiple logistic regression |
|-----------------------------------|---------------------------|-----------------------------|
|                                   | Crude OR  | 95% CI   | χ² statistics (df) | p-value  | Adj. OR  | 95% CI   | χ² statistics (df) | p-value  |
| Age (years)                       | ≤ 65      | 1.00     |                |          |          |          |                |          |
|                                  | > 65      | 3.56     | 2.78, 4.53     | 96.42 (1) | < 0.001 |          |                |          |
| Gender                            | Female    | 1.00     |                |          |          |          |                |          |
|                                  | Male      | 1.35     | 1.13, 1.61     | 11.03 (1) | 0.001   | 1.53     | 1.20, 1.96     | 11.91 (1) | 0.001 |
| Smoking Status                    | Non-smoker| 1.00     |                |          |          |          |                |          |
|                                  | Smoker    | 1.16     | 0.91, 1.48     | 1.47 (1)  | 0.225   |          |                |          |
| Comorbidity                       | No comorbidity| 1.00 |                |          |          |          |                |          |
|                                  | 1 comorbidity| 2.94 | 2.40, 3.61     | 106.8 (1) | 0.001   | 1.36     | 1.03, 1.79     | 4.91 (1)  | 0.031 |
|                                  | ≥ 2 comorbidities| 4.95 | 4.03, 6.08     | 232.2 (1) | 0.001   | 1.09     | 0.80, 1.49     | 0.41 (1)  | 0.576 |
| Worst case classification         | Stage 1   | 1.00     |                |          |          |          |                |          |
|                                  | Stage 2   | 11.91    | 6.85, 20.72    | 77.04 (1) | 0.001   | 6.50     | 3.61, 11.69    | 38.93 (1) | 0.001 |
|                                  | Stage 3   | 27.14    | 15.67, 47.03   | 138.6 (1) | 0.001   | 4.07     | 2.11, 7.84     | 17.64 (1) | 0.001 |
|                                  | Stage 4   | 138.14   | 77.59, 245.9   | 280.4 (1) | 0.001   | 10.38    | 5.08, 21.19    | 41.27 (1) | 0.001 |
|                                  | Stage 5   | 1356.93  | 605.6, 3040.6  | 307.0 (1) | 0.001   | 37.06    | 13.04, 105.3   | 44.96 (1) | 0.001 |
| White blood cell                 | Normal range| 1.00 |                |          |          |          |                |          |
|                                  | Out of normal range| 3.05 | 2.38, 3.93     | 75.72 (1) | 0.001   | 1.23     | 0.76, 1.97     | 0.35 (1)  | 0.555 |
|                                  | Not tested | 0.65 | 0.47, 0.91     | 6.45 (1)  | 0.011   | 0.19     | 0.09, 0.37     | 21.93 (1) | 0.001 |
| Platelets                         | Normal range| 1.00 |                |          |          |          |                |          |
|                                  | Out of normal range| 1.58 | 1.24, 2.01     | 13.55 (1) | < 0.001 |          |                |          |
|                                  | Not tested | 0.61 | 0.44, 0.85     | 8.49 (1)  | 0.004   |          |                |          |
| Neutrophils                       | Normal range| 1.00 |                |          |          |          |                |          |
|                                  | Out of normal range| 3.48 | 2.78, 4.35     | 119.3 (1) | < 0.001 | 2.31     | 1.51, 3.53     | 15.34 (1) | < 0.001 |
|                                  | Not tested | 1.29 | 1.00, 1.66     | 3.95 (1)  | 0.047   | 1.18     | 0.34, 4.33     | 0.06 (1)  | 0.803 |
| Lymphocytes                       | Normal range| 1.00 |                |          |          |          |                |          |
|                                  | Out of normal range| 3.34 | 2.33, 4.69     | 44.63 (1) | < 0.001 | 2.04     | 1.18, 3.51     | 6.47 (1)  | 0.011 |
|                                  | Not tested | 1.14 | 0.88, 1.47     | 7.01 (1)  | 0.317   | 4.21     | 1.08, 16.38    | 3.53 (1)  | 0.060 |
| C-reactive protein               | Normal range| 1.00 |                |          |          |          |                |          |
|                                  | Out of normal range| 14.49| 11.12, 18.87   | 392.5 (1) | < 0.001 | 3.34     | 2.33, 4.78     | 48.38 (1) | < 0.001 |
|                                  | Not tested | 3.46 | 2.83, 4.22     | 148.6 (1) | < 0.001 | 2.32     | 1.75, 3.08     | 45.69 (1) | < 0.001 |
| Duration of hospitalization      | ≤ 7 days or less | 1.00 |                |          |          |          |                |          |
|                                  | 8 to 11 days| 1.62 | 1.20, 2.19     | 9.97 (1)  | 0.002   | 1.89     | 1.26, 2.86     | 9.25 (1)  | 0.002 |
| Use of anti-viral agents         | Not administered| 1.00 |                |          |          |          |                |          |
|                                  | Administered| 22.77| 18.51, 28.02   | 1121.9 (1) | < 0.001 | 6.38     | 4.68, 8.70     | 150.5 (1) | < 0.001 |
| Use of anti-malarial agents      | Not administered| 1.00 |                |          |          |          |                |          |
|                                  | Administered| 6.46 | 5.27, 7.92     | 408.78 (1) | < 0.001 | 1.63     | 1.19, 2.25     | 9.35 (1)  | 0.002 |
| Use of anti-fungal agents        | Not administered| 1.00 |                |          |          |          |                |          |
|                                  | Administered| 20.27| 10.09, 40.74   | 96.02 (1) | < 0.001 |          |                |          |
Notably, anti-malarial and anti-viral agents were prescribed to nearly half and one-third of the COVID-19 patients, respectively. This was attributed to the interim Malaysian guidelines for clinical management of COVID-19 patients, which recommend that those with disease severity of stage 2 to 5, which is equivalent to the World Health Organization's mild to critical severity classification [28], be given hydroxychloroquine 400 mg BD for one day and followed by 200 mg twice daily (BID), and the addition of lopinavir/ritonavir 2 BID, and ribavirin 2.4 g immediately and 1.2 g BID if needed after consulting with an infectious disease physician [16]. Initial evidence suggested that the anti-viral properties of hydroxychloroquine were associated with a significant reduction of viral load and that this effect could be enhanced by combining with azithromycin [34]. Nevertheless, a combination of azithromycin and hydroxychloroquine was not included in the recommendation of the interim Malaysian guidelines for clinical management of COVID-19, and hence the usage of azithromycin was low (8.3 to 9.7%).

The patients who were more ill tended to get antibiotic coverage as their inflammatory markers were elevated, they had a longer duration of hospitalization, were given anti-viral and anti-malarial agents, were treated in the ICU and required corticosteroids. These factors are consistent with regard to the interim Malaysia Ministry of Health guidelines for patients who are critically ill. The recommendation was to consider starting on antibiotics [35]. Chedid et al. showed in the meta-analysis that the higher the severity in terms of clinical severity, the higher the number of patients who were given antibiotics (severe 100% vs. moderate 67.9%) [23]. Elevated inflammatory markers such as CRP and procalcitonin, together with leukocytosis and increased neutrophil count, were associated with higher antibiotic prescriptions [21, 36]. This could be due to the cytokine release syndrome that produces signs and symptoms that may be difficult to distinguish from sepsis or septic shock due to bacterial infections. Suleyman et al. and Seaton et al. found that comorbidities were also a factor taken into consideration by clinicians before starting antibiotics [37, 38].

Limitations
Some inevitable limitations associated with the extraction of data from a large national database include missing data and possibly some inaccurate information entered. Nevertheless, the clinical records of COVID-19 were entered into the database in real time by the medical officer in-charge, and recall bias was avoided. The information regarding antibiotic dosage, duration of therapy, and imaging studies was incomplete and, thus, analysis in that aspect was impossible, albeit very important. There was a lack of laboratory information for some of the patients during the early phase of the pandemic, especially cultures for bacterial infection and inflammatory biomarkers. Data on this were sparse and inconsistent among institutions due to a lack of clear procedures for handling microbiological specimens early in the pandemic. Future studies should evaluate the rationale of antibiotic treatment based on bacterial culture identification and identify the possibility of antibiotic resistance in COVID-19 patients treated with antibiotics.

Conclusions
This study demonstrated that antibiotic prescribing in Malaysia during the early phase of the pandemic was low compared to other countries. In line with the guidelines for antibiotic prescribing for community-acquired pneumonia to cover for bacterial co-infection

### Table 5 (continued)

| Variables          | Simple logistic regression | Multiple logistic regression |
|--------------------|----------------------------|------------------------------|
|                    | Crude OR 95% CI            | Adj. OR 95% CI               |
|                    | $\chi^2$ statistics (df)$^a$ | $\chi^2$ statistics (df)$^b$ |
|                    | $p$-value$^a$              | $p$-value$^b$                |
| Corticosteroid therapy | Not administered | 1.00 | 1.00 |
|                    | Administered              | 38.70 | 22.73, 65.91 | 306.6 (1) | $< 0.001$ | 3.05 | 1.48, 6.25 | 10.15 (1) | 0.001 |
| ICU/HDU admission  | No                        | 1.00 | 1.00 |
|                    | Yes                       | 71.41 | 42.45, 120.1 | 558.3 (1) | $< 0.001$ | 2.73 | 1.34, 5.58 | 8.05 (1) | 0.005 |
| Oxygen therapy     | No                        | 0.00 |
|                    | Yes                       | 22.29 | 17.71, 28.05 | 799.9 (1) | $< 0.001$ | – | – | – | – |

* OR odds ratio, CI confidence interval, ICU/HDU Intensive Care Unit/High Dependency Unit

$^a$ Likelihood ratio test

$^b$ Wald test
during viral pneumonia, the choice of antibiotics for patients suspected of having bacterial co-infection was amoxicillin/clavulanic acid, and the choice of antibiotic for escalation was piperacillin/tazobactam. Males with a comorbidity who were more ill, given anti-viral and anti-malarial agents, admitted to the HDU/ICU, prescribed corticosteroids, and having deranged blood parameters such as neutrophil, lymphocyte, and CRP, associated with a higher odds of receiving antibiotics.

Abbreviations
ICU: Intensive Care Unit; HDU: High Dependency Unit; CRP: C-reactive protein.

Acknowledgements
The team thanks all staff in Clinical Research Centre Hospital Sungai Buloh who assisted in the extraction of data from the database. The team would like to thank Dr Philip Rajan for critically reviewing the manuscript. The team would also like to thank the Director General of Health, Malaysia, for his permission to publish this article.

Authors’ contributions
INM, CKWW, CCC, ELL, CLL and HBK contributed to the idea and drafting of the study protocol. INM, CHM, KC and CCC contributed to data management. CCC was involved in data analysis. CKWW, CCC, ELL and LBH contributed to the writing of the report. CLL and HBK contributed to the critical revision of the report. All authors read, reviewed and approved the final version.

Funding
The authors received no funding for conducting this research.

Availability of data and materials
The datasets used and/or analysed with permission to support the finding of this study are available from Clinical Research Centre Hospital Sungai Buloh but restrictions apply to the availability of these data, which were used under permission for this study, and are not publicly available. Data, however, are available from the authors upon reasonable request and with permission of the Infectious Diseases Unit or Clinical Research Centre Hospital Sungai Buloh.

Declarations
Ethics approval and consent to participate
Approval to conduct this study was obtained from the Medical Research Ethics Committee, Ministry of Health Malaysia with the protocol number NMRR-20-2124-56531 (IR). Written informed consent from each patient was available from the authors upon reasonable request and with permission of the Infectious Diseases Unit or Clinical Research Centre Hospital Sungai Buloh.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical Department, Hospital Raja Permaisuri Bainun, Ministry of Health, Ipoh, Malaysia. 2 Clinical Research Centre, Hospital Raja Permaisuri Bainun, Ministry of Health, Ipoh, Malaysia. 3 Infectious Diseases Unit, Medical Department, Hospital Raja Permaisuri Bainun, Ministry of Health, Ipoh, Malaysia.

Received: 23 November 2021 Accepted: 5 January 2022

Published online: 11 January 2022

References
1. World Health Organization. Coronavirus disease 2019 (COVID-19): Situation Report 101. Geneva, Switzerland; 2020. https://www.who.int/ emergencies/diseases/novel-coronavirus-2019/situation-reports
2. Musuza J, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. PLoS ONE. 2021;16:e0251170. https://doi.org/10.1371/journal.pone.0251170.
3. Cong W, Poudel AN, Alhusein N, Wang H, Yao G, Lambert H. Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: rapid review and evidence synthesis. medRxiv. 2021;2021215192.
4. Langford B, So M, Raybordhan S, Leung V, Soucy J-P, Westwood D, et al. Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis. Clin Microbiol Infect. 2021;27:520–31.
5. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81. https://doi.org/10.1016/S2213-2600(20)30079-5.
6. Nadrah K, Rubulotta F, Belliato M. Antibiotic use in patients with COVID-19: a ‘snapshot’ Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75:56–10.
7. Abellana- Alonso G, Padulles A, Rombauts A, Gudiel C, Pulido M, Alvarez-Pouso C, et al. Antibiotic prescription during the COVID-19 pandemic: a biphasic pattern. Infect Control Hosp Epidemiol. 2020;41:1371–2.
8. Doidge JC, Gould DW, Fernando-Vivas P, Mouncey PR, Thomas K, Shankar-Hari M, et al. Trends in intensive care for patients with covid-19 in England, Wales, and Northern Ireland. Am J Respir Crit Care Med. 2021;203:565–74. https://doi.org/10.1164/rccm.202008-3212OC.
9. Abu-Rub LJ, Abdelrahman HA, Johar ARA, Alhusssan HA, Hadhi HA, Elhai NO. Antibiotics prescribing in intensive care settings during the covid-19 era: a systematic review. Antibiotics. 2021;10:1–13.
10. Goncalves Mendes Neto A, Lo KB, Watton A, Salacup G, Pelayo J, Dejoy R, et al. Bacterial infections and patterns of antibiotic use in patients with COVID-19. J Med Virol. 2021;93:1489–95.
11. Beovic B, Doušák M, Ferreira-Coimbra J, Nadrah K, Rubulotta F, Belliato M, et al. Antibiotic use in patients with COVID-19: a “snapshot” Infectious Diseases International Research Initiative (ID-IRI) survey. J Antimicrob Chemother. 2020;75:3386–90.
12. Calderón-Parra J, Muñoz-Miguez A, Bendala-Estrada AD, Ramos-Martínez A, Muñez-Rubio E, Fernández Carracedo E, et al. Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMI-COVID. medRxiv. 2021;16:e0251340. https://doi.org/10.1371/journal.pone.0251340.
13. Martin AJ, Shulder S, Dobrzenski D, Quartuccio K, Killinger KE. Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients. J Pharm Pract. 2021. https://doi.org/10.1177/08971900211030248.
14. World Health Organization (WHO). Clinical management Clinical management Living guidance COVID-19. Geneva, Switzerland. 2021. https://www.who.int/publications/item/WHO-2019-nCoV-clinical-2021-1
15. Ministry of Health Malaysia. Guidelines COVID-19 Management in Malaysia No. 5/2020. 2020. http://covid-19.moh.gov.my/gans-panduan/gans-panduan-kkm
16. Ministry of Health Malaysia. Guidelines COVID-19 Management No.5/2020 updated on 24 March 2020. Putrajaya, Malaysia, 2020.
17. Naing L, Winn T, Rusli BN. Practical issues in calculating the sample size for prevalence studies. Arch Orofac Sci. 2006;1:9–14.
18. Hashim JH, Adman MA, Hashim Z, Mohd Radi MF, Kwan SC. COVID-19 epidemic in Malaysia: epidemic progression, challenges, and response. Front Public Health. 2021;9:247.
19. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England). 2020;395:507–13.
20. Liu K, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020;133:1025–31.
21. Asmarawati TP, Risyid AN, Suryantoro SD, Mahdi BA, Windradi C, Wulangrimu PA, et al. The clinical impact of bacterial co-infection among
moderate, severe and critically ill COVID-19 patients in the second referral hospital in Surabaya. F1000Research. 2021;10:113.

22. Zhou P, Liu Z, Chen Y, Xiao Y, Huang X, Fan XG. Bacterial and fungal infections in COVID-19 patients: a matter of concern. Infect Control Hosp Epidemiol. 2020;41:1124–5.

23. Chedid M, Waked R, Haddad E, Chetata N, Saibia G, Choucair J. Antibiotics in treatment of COVID-19 complications: a review of frequency, indications, and efficacy. J Infect Public Health. 2021;14:570–6.

24. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect. 2020;26:1622–9.

25. Mahmooudi H. Bacterial co-infections and antibiotic resistance in patients with COVID-19. GMS Hgy Infect Control. 2020;15:Doc35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7747008/pdf/HIC-15-35.pdf

26. Karami Z, Knoop BT, Dofferhoff ASM, Blaauw MJT, Janssen NA, van Apeldoorn M, et al. Few bacterial co-infections but frequent empiric antibiotic use in the early phase of hospitalized patients with COVID-19: results from a multicentre retrospective cohort study in The Netherlands. Infect Dis (London, England). 2021;53:102–10.

27. García-Vidal C, Sanjuan G, Moreno-García E, Puerta-Alcalde P, García-Poutron N, Chummba M, et al. Incidence of co-infections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. Clin Microbiol Infect. 2021;27:83–8.

28. World Health Organization. Clinical management of COVID-19: Interim guidance. Geneva: World Health Organisation; 2020.

29. Ministry of Health Malaysia. Clinical Management of Confirmed COVID-19 Case in Adults and Pediatrics [Internet]. Putrajay, Malaysia; 2021. https://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/ANNEX_2e_CLINICAL_MANAGEMENT_OF_CONFIRMED_COVID-19_CASE_IN_ADULT_AND_PAEDIATRIC_13082021.pdf

30. Ministry of Health Malaysia. National Antimicrobial Guideline [Internet]. Petaling Jaya: Pharmaceutical Services Program. Ministry of Health Malaysia; 2019. www.pharmacy.gov.my

31. Estrada ADR, Parra JCC, Carracedo EF, Míguez AM, Martínez AR, Rubio EM, et al. Inadequate use of antibiotics in the COVID-19 era: effectiveness of antibiotic therapy. BMC Infect Dis. 2021. https://doi.org/10.21203/rs.3.rs-244297/v1.

32. Molla MMA, Yeasmin M, Islam MK, Sharif MM, Nafisa T, et al. Antibiotic prescribing patterns at COVID-19 dedicated wards in bangladesh: findings from a Single Center Study. Infect Prev Pract. 2021;3:100134.

33. Liu C, Wen Y, Wan W, Lei J, Jiang X. Clinical characteristics and antibiotics treatment in suspected bacterial infection patients with COVID-19. Int Immunopharmacol. 2021;90:107157.

34. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56:105949.

35. Ministry of Health Malaysia. Annex 29. Intensive Care Preparedness and Management for COVID-19: [Internet]. Putrajaya: Ministry of Health Malaysia; 2020. http://covid-19.moh.gov.my/garis-panduan/garis-panduan-kkm/Annex_29_Intensive_Care_Preparedness_and_Management_for_COVID-19_3.11.2020.pdf

36. Wang S, Xie Z, Shen Z. Serum procalcitonin and C-reactive protein in the evaluation of bacterial infection in generalized pustular psoriasis. An Bras Dermatol. 2019;94:542–8. https://doi.org/10.1016/j.abd.2019.09.022.

37. Suleyman G, Fadel RA, Malette KM, Hammond C, Abdulla H, Entz A, et al. Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan detroit. JAMA Netw Open. 2020;3:e2012270.

38. Seaton RA, Gibbons CL, Cooper L, Malcolm W, McKinnon R, Dundas S, et al. Survey of antibiotic and antifungal prescribing in patients with suspected and confirmed COVID-19 in Scottish hospitals. J Infect. 2020;81:952–60.